Bridging therapy-induced phenotypes and genetic immune dysregulation to study interleukin-2-induced immunotoxicology
Clinical Immunology · 2024
DOI: 10.1016/j.clim.2024.110288 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Immunology, 2024. Verfasst von Charline Sommer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), M…. Hauptthemen laut MEDLINE: Interleukin-2, Killer Cells, Natural. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Innovative Medicines Initiative, European Commission, European Federation of Pharmaceutical Industries and Associations.
Abstract (Originalsprache)
Interleukin-2 (IL-2) holds promise for the treatment of cancer and autoimmune diseases, but its high-dose usage is associated with systemic immunotoxicity. Differential IL-2 receptor (IL-2R) regulation might impact function of cells upon IL-2 stimulation, possibly inducing cellular changes similar to patients with hypomorphic IL2RB mutations, presenting with multiorgan autoimmunity. Here, we show that sustained high-dose IL-2 stimulation of human lymphocytes drastically reduces IL-2Rβ surface expression especially on T cells, resulting in impaired IL-2R signaling which correlates with high IL-2Rα baseline expression. IL-2R signaling in NK cells is maintained. CD4+ T cells, especially regulatory T cells are more broadly affected than CD8+ T cells, consistent with lineage-specific differences in IL-2 responsiveness. Given the resemblance of cellular characteristics of high-dose IL-2-stimulated cells and cells from patients with IL-2Rβ defects, impact of continuous IL-2 stimulation on IL-2R signaling should be considered in the onset of clinical adverse events during IL-2 therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL), Member of the Frau…
- Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Luxembourg.
Förderung
- Innovative Medicines Initiative
- European Commission
- European Federation of Pharmaceutical Industries and Associations
- Juvenile Diabetes Research Foundation United States of America
Zitieren
APA
Sommer, C., Jacob, S., Bargmann, T., Shoaib, M., Alshaikhdeeb, B., Satagopam, V. P., Dehmel, S., Neuhaus, V., Braun, A., & Sewald, K. (2024). Bridging therapy-induced phenotypes and genetic immune dysregulation to study interleukin-2-induced immunotoxicology. Clinical Immunology. https://doi.org/10.1016/j.clim.2024.110288
Vancouver
Sommer C, Jacob S, Bargmann T, Shoaib M, Alshaikhdeeb B, Satagopam VP, et al. Bridging therapy-induced phenotypes and genetic immune dysregulation to study interleukin-2-induced immunotoxicology. Clinical Immunology. 2024. doi:10.1016/j.clim.2024.110288
BibTeX
@article{Sommer2024,
author = {Sommer, Charline and Jacob, Sophie and Bargmann, Tonia and Shoaib, Muhammad and Alshaikhdeeb, Basel and Satagopam, Venkata P and Dehmel, Susann and Neuhaus, Vanessa and Braun, Armin and Sewald, Katherina},
title = {Bridging therapy-induced phenotypes and genetic immune dysregulation to study interleukin-2-induced immunotoxicology},
journal = {Clinical Immunology},
year = {2024},
doi = {10.1016/j.clim.2024.110288}
}
EUVIMED